title: Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.
abstract: The advent of novel therapeutics that specifically target signaling pathways activated by genetic alterations has revolutionized the way patients with lung cancer are treated. Although only few and largely ineffective chemotherapeutic regimens were available 10 years ago, a lung tumor diagnosed today requires extensive pathologic subtyping and diagnosis of genome alterations to afford more effective treatment (eg, in EGFR-mutant adenocarcinoma). This change of paradigm has several profound implications, ranging from preclinical work on the mechanism of action to a novel, more biologically oriented taxonomy and from genome diagnostics to trial design. Here, we have summarized these developments into six conceptual paradigms that illustrate the transition from empirical cancer medicine to mechanistically based individualized oncology.
authors.affiliation: Center of Integrated Oncology Köln-Bonn, University of Cologne, Weyertal 115b, 50931 Cologne, Germany.
authors.forename: Reinhard
authors.initials: R
authors.lastname: Buettner
authors.forename: Jürgen
authors.initials: J
authors.lastname: Wolf
authors.forename: Roman K
authors.initials: RK
authors.lastname: Thomas
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D066246:ErbB Receptors / Q000235:genetics; D023281:Genomics / Q000379:methods*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D008495:Medical Oncology / Q000379:methods; D062346:Molecular Medicine / Q000379:methods; D009154:Mutation; D057285:Precision Medicine / Q000379:methods; D057170:Translational Research, Biomedical / Q000379:methods
chemical_list: D066246:ErbB Receptors